Glenmark launches Akynzeo in Nepal, India
Glenmark Pharmaceuticals has launched Akynzeo, a drug used for prevention of chemotherapyinduced nausea and vomiting, in India and Nepal under an exclusive licensing pact with Swiss pharma group, Helsinn.
Akynzeo is an oral fixed combination of netupitant 300 mg and palonosetron 0.5 mg. It is administered in a single capsule and offers 5-day prophylaxis from of both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV).
The drug is already being marketed in the EU, the US, and several other leading markets of the world. The product has been developed by Helsinn, and Glenmark has exclusive marketing rights for it in India and Nepal.